Novo Nordisk (NOV) Stock Statistics & Valuation Metrics

Novo Nordisk has a market cap or net worth of CHF144.02B. The enterprise value is CHF1.49M.

Novo Nordisk has 3,390,128,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Novo Nordisk’s return on equity (ROE) is 0.53 and return on invested capital (ROIC) is 29.53%.

The current PE Ratio of Novo Nordisk is 9.6. Novo Nordisk’s PEG ratio is ―.

In the last 12 months, Novo Nordisk had revenue of 309.06B and earned 102.43B in profits. Earnings per share was 23.06.

In the last 12 months, operating cash flow was 133.01B and capital expenditures -84.09B, giving a free cash flow of 48.92B billion.

Novo Nordisk pays an annual dividend of ―, resulting in a dividend yield of ―

Novo Nordisk upcoming earnings date is Nov 4, 2026, Before Open (Confirmed).

Novo Nordisk as a current ratio of 0.80, with Debt / Equity ratio of 63.33%

In the past 12 months, Novo Nordisk has paid 28.11B in taxes.

Novo Nordisk EV to EBITDA ratio is 10.37, with an EV/FCF ratio of 53.45.

Novo Nordisk has CHF44.98B in cash and marketable securities with CHF118.72B in debt, giving a net cash position of -CHF95.14B billion.

Gross margin is 80.65%, with operating margin of 41.30%, and net profit margin of 33.14%.

The average price target for Novo Nordisk is CHF36.33, which is 11.43% higher than the current price. The consensus rating is Hold